IRVINE, Calif.--(BUSINESS WIRE)--Advanced melanoma patients who received an experimental patient-specific tumor stem cell therapy as part of several clinical trials experienced superior survival rates compared to patients who did not receive the therapy, according to a presentation by Robert Dillman, MD, during the Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, Maryland.
Help employers find you! Check out all the jobs and post your resume.
